EP1339404A2 - Composition et methode - Google Patents

Composition et methode

Info

Publication number
EP1339404A2
EP1339404A2 EP01992146A EP01992146A EP1339404A2 EP 1339404 A2 EP1339404 A2 EP 1339404A2 EP 01992146 A EP01992146 A EP 01992146A EP 01992146 A EP01992146 A EP 01992146A EP 1339404 A2 EP1339404 A2 EP 1339404A2
Authority
EP
European Patent Office
Prior art keywords
day
deterioration
cognitive function
composition
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01992146A
Other languages
German (de)
English (en)
Inventor
Steven Curtis Zicker
Karen J. Wedekind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/922,633 external-priority patent/US20020052402A1/en
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of EP1339404A2 publication Critical patent/EP1339404A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components. These components can be administered in the diet or taken separately orally.
  • composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or r c. reverse deterioration of cognitive function
  • a further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
  • an antioxidant is a material that quenches a free radical.
  • examples of such materials are beta-carotene, selenium, coenzyme Q10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1- carnitine and the like.
  • Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like.
  • the alpha form is preferable but beta, gamma and delta forms can be included.
  • the d form is preferable but racemic mixtures are acceptable.
  • the forms and derivatives will function in a Vitamin E like activity after ingestion.
  • Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human. They can be in any form such as liquid, semisolid, solid and heat stable form.
  • Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621, 117, racemic mixtures, salts, esters or amides thereof.
  • L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinate s, as well as acetylated carnitine, and the like can be used.
  • the quantities administered to the human are calculated as the active material, per se, that is measured as specific material.
  • the minimum amounts employed should not bring about toxicity.
  • Vitamin E minimum is about 50 or 100 or 150 mg/day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed.
  • Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/day.
  • Alpha lipoic acid can be administered up to about 10 or 20 mg/kg body weight/ day. Minimums are about .5 or 1 mg/kg body weight/ day.
  • L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and l-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
  • Beta-carotene at least about 0.02 mg/kg body weight/ day 1-15 ppm can be employed.
  • Lutein at least about 5 ppm mg/kg body weight/ day can be employed.
  • Tocotrienols at least about 0.5 mg/kg body weight/ day can be employed.
  • Coenzyme Q10 at least about 0.5 mg/kg body weight/ day can be employed.
  • S-adenosylmethionine at least about 1.0 mg/kg body weight/ day can be employed.
  • Taurine at least about 10 mg/kg body weight/ day can be employed.
  • Soy isoflavones at least about 0.5 mg/kg body weight/ day can be used.
  • N-acetylcysteine at least about 1.0 mg/kg/ body weight/ day can be used.
  • Glutathione at least about 1.0 g/kg body weight/ day can be used.
  • Ginkgo Biloba at least 1.0 mg/kg body weight/ day can be used.
  • the quantities can be administered in a typical "one a day" dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons. Additionally, it can be administered in a food such as snack bars, cereals, and the like.
  • Example 1
  • a supplement or food providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of l-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45.
  • age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health care provider, are observed.
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living
  • Pfeiffer's mental status questionnaire or other pertinent tests as
  • MME Folstein's Mini-mental State Exam
  • WMS Wechsler Memory Scale
  • Katz' scale of activities of daily living Lawton's scale of instrumental activities of daily living

Abstract

L'invention concerne une composition renfermant un antioxydant ou un mélange d'antioxydants en quantités suffisantes pour prévenir, inhiber, ou inverser la détérioration de la fonction cognitive.
EP01992146A 2000-10-31 2001-10-30 Composition et methode Withdrawn EP1339404A2 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US922633 1986-10-24
US24451100P 2000-10-31 2000-10-31
US244511P 2000-10-31
US25344600P 2000-11-28 2000-11-28
US25344700P 2000-11-28 2000-11-28
US253446P 2000-11-28
US253447P 2000-11-28
US09/922,633 US20020052402A1 (en) 2000-10-31 2001-08-06 Composition and method
PCT/US2001/048665 WO2002043666A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Publications (1)

Publication Number Publication Date
EP1339404A2 true EP1339404A2 (fr) 2003-09-03

Family

ID=27500158

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01992146A Withdrawn EP1339404A2 (fr) 2000-10-31 2001-10-30 Composition et methode

Country Status (6)

Country Link
EP (1) EP1339404A2 (fr)
JP (1) JP2004514686A (fr)
CN (1) CN1477958A (fr)
AU (1) AU2002232616A1 (fr)
CA (1) CA2427470A1 (fr)
WO (1) WO2002043666A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005185188A (ja) * 2003-12-25 2005-07-14 Nichirei Corp アセロラ処理物およびｌ−カルニチン含有組成物
RU2350124C2 (ru) * 2004-01-28 2009-03-27 Нестек С.А. Питательная композиция для улучшения состояния кожи и предотвращения кожных заболеваний
AU2005309502B2 (en) * 2004-11-24 2011-11-17 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
DK1817058T3 (en) * 2004-11-24 2015-12-07 Hills Pet Nutrition Inc COMPOSITION FOR USE FOR IMPROVING THE hepatic clearance xenobiotics WITH AN ANIMAL
CN101287460B (zh) * 2005-08-17 2012-04-25 希尔氏宠物营养品公司 预防和治疗肾病的组合物
CN1895671B (zh) * 2005-12-08 2012-11-28 淮北辉克药业有限公司 治疗病毒型肝病的复方制剂
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
JPWO2008099469A1 (ja) * 2007-02-14 2010-05-27 株式会社プロジェクト・エム 赤血球の脂質過酸化を抑制するための組成物および方法
CN102469807A (zh) * 2009-07-14 2012-05-23 希尔氏宠物营养品公司 包括持续释放的硫辛酸的宠物食品组合物及其制造和使用方法
KR20140019827A (ko) 2011-04-05 2014-02-17 론자 아게 (론자 엘티디.) 피로를 감소 또는 예방하고 인지 기능을 개선시키기 위한 l-카르니틴, 그의 염 및 유도체의 용도
EP2508179A1 (fr) 2011-04-05 2012-10-10 Lonza Ltd. Utilisation de carnitine L, sels et dérivés associés pour réduire ou empêcher la fatigue et améliorer la fonction cognitive
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06199690A (ja) * 1992-03-06 1994-07-19 Yunie:Kk 脳代謝促進・脳機能改善剤
DE4343592C2 (de) * 1993-12-21 1998-04-16 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure und dessen Metaboliten in Form der freien Säure oder als Salze oder Ester oder Amide zur Behandlung von Glukosestoffwechselstörungen des zentralen Nervensystems
FR2721516B1 (fr) * 1994-06-27 1996-09-13 Inst Rech Biolog Sa Nouvelles utilisations d'un complexe à base de phospholipides cérébraux en thérapeutique et dans l'alimentation.
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
ATE247953T1 (de) * 1999-03-16 2003-09-15 Merck Patent Gmbh Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
WO2000057876A1 (fr) * 1999-03-26 2000-10-05 Lipogenics, Inc. Preparations antioxydantes et procedes d'utilisation de telles preparations
DE19920316A1 (de) * 1999-05-03 1999-12-09 Heinz Kiefer Arzneimittel als Antioxidans mit einer Vitamin-Spurenelement-Kombination zur Förderung der Funktionstüchtigkeit der Zellen
CA2377414A1 (fr) * 1999-06-15 2000-12-21 John D. Potter Compositions de nutriments destines a reduire le risque de maladie, traitement associe, et methode de selection des constituants
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
JP2003529347A (ja) * 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
HU227182B1 (en) * 2000-03-06 2010-09-28 Andras Javor Lecitin-ascorbic acid combination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.H. BEERS, R. BERKOW: "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J. *
See also references of WO0243666A3 *

Also Published As

Publication number Publication date
CA2427470A1 (fr) 2002-06-06
CN1477958A (zh) 2004-02-25
AU2002232616A1 (en) 2002-06-11
JP2004514686A (ja) 2004-05-20
WO2002043666A3 (fr) 2003-01-30
WO2002043666A2 (fr) 2002-06-06

Similar Documents

Publication Publication Date Title
US9278109B2 (en) Compositions and methods for the prevention of cardiovascular disease
US6121249A (en) Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
EP1339404A2 (fr) Composition et methode
US20020076470A1 (en) Composition and method
US20040082649A1 (en) Formulation and delivery method to enhance antioxidant potency of Vitamin E
US6323188B1 (en) Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
US20060116334A1 (en) Folate based composition for treatment of the cardiovascular system
EP2869717B1 (fr) Prévention d'une réaction à l'alcool avec des compléments diététiques
US10052316B2 (en) Methods and compositions for treatment of mitochondrial toxicity
EP1331855B1 (fr) Composition pour animaux de compagnie agés
WO2001021208A1 (fr) Supplement nutritionnel fournissant une energie et une endurance accrues
EP1248609A1 (fr) Traitement de la perte de memoire benigne
ES2546055T3 (es) Complementos nutricionales para individuos de 50 años o más para mejorar la vitalidad, la inmunidad, la salud ocular y ósea
Janson Orthomolecular medicine: the therapeutic use of dietary supplements for anti-aging
US20080181972A1 (en) Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
US20130084272A1 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
JP2008214338A (ja) 高次脳機能低下改善剤および遅延記憶低下改善剤
US20020076469A1 (en) Composition and method
US20020052402A1 (en) Composition and method
BR112020016923A2 (pt) Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição
US7628984B2 (en) Micronutrient formulations for pulmonary and heart health
US7399755B2 (en) Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same
US20110274791A1 (en) Multivitamin/mineral formulation to combat the effects of environmental stress; improved immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
ZA200303749B (en) Compositions containing an antioxidant such as alpha lipoic acid, carnitine, Vitamin C or Vitamin E for preventing or inhibiting loss of cognitive function.
US6358997B1 (en) Tocopherol and tocotrienol compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030528

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040430

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061228